INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.